JP2023539596A5 - - Google Patents
Info
- Publication number
- JP2023539596A5 JP2023539596A5 JP2023513414A JP2023513414A JP2023539596A5 JP 2023539596 A5 JP2023539596 A5 JP 2023539596A5 JP 2023513414 A JP2023513414 A JP 2023513414A JP 2023513414 A JP2023513414 A JP 2023513414A JP 2023539596 A5 JP2023539596 A5 JP 2023539596A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2013477.1A GB202013477D0 (en) | 2020-08-27 | 2020-08-27 | Nucleic acid constructs for expressing polypeptides in cells |
| GB2013477.1 | 2020-08-27 | ||
| PCT/EP2021/073714 WO2022043483A1 (en) | 2020-08-27 | 2021-08-27 | Nucleic acid constructs for expressing polypeptides in cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539596A JP2023539596A (ja) | 2023-09-15 |
| JPWO2022043483A5 JPWO2022043483A5 (https=) | 2024-09-03 |
| JP2023539596A5 true JP2023539596A5 (https=) | 2024-09-03 |
Family
ID=72749810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513414A Pending JP2023539596A (ja) | 2020-08-27 | 2021-08-27 | 細胞においてポリペプチドを発現させるための核酸構築物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250144137A1 (https=) |
| EP (1) | EP4204438A1 (https=) |
| JP (1) | JP2023539596A (https=) |
| CN (1) | CN116209455A (https=) |
| AU (1) | AU2021335027A1 (https=) |
| CA (1) | CA3190502A1 (https=) |
| GB (2) | GB202013477D0 (https=) |
| TW (1) | TW202227469A (https=) |
| WO (1) | WO2022043483A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| WO2022221669A1 (en) * | 2021-04-15 | 2022-10-20 | Kyverna Therapeutics, Inc. | Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents |
| WO2023180690A1 (en) | 2022-03-22 | 2023-09-28 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| EP4519417A1 (en) * | 2022-05-05 | 2025-03-12 | Quell Therapeutics Limited | Method for maintaining suppressive activity of regulatory t cells |
| WO2024196815A1 (en) * | 2023-03-21 | 2024-09-26 | The Regents Of The University Of California | Method for suppressing immune responses to transplanted cells, tissues and organs |
| WO2024194649A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t cells and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| WO2005001048A2 (en) | 2003-06-13 | 2005-01-06 | Oncomax Acquisition Corp. | Preparation and application of anti-tumor bifunctional fusion proteins |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| MX2007014673A (es) | 2005-05-24 | 2008-04-08 | Avestha Gengraine Tech Pvt Ltd | Metodo para la produccion de un anticuerpo monoclonal para cd20 para el tratamiento de linfoma de celular b. |
| JP5626164B2 (ja) | 2011-07-26 | 2014-11-19 | 日本精工株式会社 | ステアリングコラム用支持装置 |
| GB201206559D0 (en) * | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| US10604586B2 (en) | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
| EP3263595A1 (en) * | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| SG11201912010XA (en) * | 2017-06-12 | 2020-01-30 | Obsidian Therapeutics Inc | Pde5 compositions and methods for immunotherapy |
| EP3697820A4 (en) * | 2017-10-17 | 2022-01-05 | The General Hospital Corporation | PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| EP3883955A1 (en) * | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
| MX2021009357A (es) * | 2019-02-04 | 2021-11-17 | Ksq Therapeutics Inc | Dianas de genes de combinacion para mejorar la inmunoterapia. |
-
2020
- 2020-08-27 GB GBGB2013477.1A patent/GB202013477D0/en not_active Ceased
-
2021
- 2021-08-27 CA CA3190502A patent/CA3190502A1/en active Pending
- 2021-08-27 US US18/042,927 patent/US20250144137A1/en active Pending
- 2021-08-27 JP JP2023513414A patent/JP2023539596A/ja active Pending
- 2021-08-27 WO PCT/EP2021/073714 patent/WO2022043483A1/en not_active Ceased
- 2021-08-27 CN CN202180063446.7A patent/CN116209455A/zh active Pending
- 2021-08-27 AU AU2021335027A patent/AU2021335027A1/en active Pending
- 2021-08-27 EP EP21770163.0A patent/EP4204438A1/en active Pending
- 2021-08-27 GB GB2303798.9A patent/GB2614158B/en active Active
- 2021-08-27 TW TW110131905A patent/TW202227469A/zh unknown